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follow-up time was 175.5 days (range 19-1402 days). Kaplan-
Meier estimates were used for engraftment, relapse, TRM, OS
and RFS rates with all patients who expired before engraftment
counted as engraftment failures. Patients were also stratiﬁed by
risk status. Results are summarized below. These results dem-
onstrate that HSCT using unrelated PD UCB can be performed
safely with outstanding results in pediatric patients with malig-
nancies.
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Reduced-intensity stem cell transplantation (RIST) from un-
related donors (UD) is shown to be feasible treatment option for
acute myelogenous leukemia/myelodysplastic syndrome (AML/
MDS). Although morbidity and mortality from graft-versus-
host disease (GVHD) may be still signiﬁcant, transplant from
UD may carry more potent graft-versus-leukemia (GVL) effect.
Patients and Method A total of 36 patients (median age: 59
years old, range: 2-69) with AML/MDS were transplanted with
RIST using related and unrelated donors. Patients were condi-
tioned with ﬂudarabine (125mg/m2), intravenous busulfan
(6.4mg/kg), and total lymphoid irradiation (2-4Gy) (Flu/Bu/
TLI). Tacrolimus and methotrexate were given as prophylaxis
for GVHD. Twenty patients underwent RIST in complete
remission (CR), and remaining 16 patients in non-CR. Related
donors (RD) were used in 16 patients (8 in CR and 8 in non-CR
at transplantation), and UD in 20 patients (12 were in CR and
8 in non-CR at transplantation).
Results The median follow-up of survivors was 971 days
(range: 109-1489), while 14 patients relapsed between 16 and
794 days (median 181 days). Overall survival (OS) and disease-
free survival (DFS) at 2 years after RIST were 29.5% and
28.5%, repsectively. The incidence of acute GVHD was rela-
tively low (grade 0: 58%, grade 1: 19%, grade 2: 14%: grade 3-4:
8%). A survival advantage was seen for UD compared to RD
(DFS at 2 years: 42.0% versus 9.2%, log-rank P0.009). The
relapse rate after RIST from RD was 71%, while from UD was
23%. The following factors were analyzed by univariate and
multivariate analyses: age, sex, disease status at transplantation,
source of stem cells (peripheral blood or bone marrow), RD or
UD, number of CD34 positive cells transplanted, and acute
GVHD. In univariate analysis, RD, non-CR at transplant, and
low cell doses transplanted (less than 5  106 /kg of CD34
positive cells), were identiﬁed as poor prognostic factors for
DFS. In multivariate analysis, RD (P0.029), non-CR at trans-
plantation (P0.020), and low cell doses (P0.030) were iden-
tiﬁed as independent risk factors for DFS. Complete donor
chimerism was achieved more consistently by day 100 in trans-
plants from UD than from RD (P0.044).
Conclusion Our observations suggest that RIST using
Flu/Bu/TLI from UD is a feasible transplant option for AML/
MDS patients, with possibly more potent GVL effect than using
RD through early achievement of complete donor chimerism.
Unrelated versus related donors in RIST for AML/MDS
Stem cell source
Acute
GVHD
(grade2-4)
NRM
at 2yr
relapse
at 2yr
2yr
DFS
Unrelated donors
(UD) 25% 32% 23% 42%
Related donors
(RD) 19% 32% 71% 9%
NRM indicates non relapse mortality. NRM and relapse rate are
evaluated by the cumulative incidence using Gray’s method.
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Optimized preparative regimens and supportive care have al-
lowed more MDS patients access to potentially curative stem cell
transplantation. Early relapse accounts for up to 30% of advanced
MDS. Leukemia induction chemotherapy prior to transplant re-
duces relapse incidence but with increased TRM. 5-Azacytidine
(5Aza) in advanced MDS may delay disease progression to AML,
has a signiﬁcant response, reduces marrow blast counts, often
within the ﬁrst 2-4 cycles, and is well tolerated. We examined the
use of pre-transplant cytoreduction with 5Aza in Int-2 or High risk
MDS and secondary AML. Patients received at least 4 cycles of
5Aza. Patients with improving marrow blast counts continued on
5Aza to best response(n10), those with greater than 20% blasts
were treated with FLAG(n7), and 5Aza patients with progressive
blast counts crossed over to FLAG(n5). Patients achieving CR/
VGPR proceeded to transplant. 22 patients (median age 49 range
16-68) were followed from the initiation of treatment. With a
median follow up of 535 days (range 36 to 1435), EFS of both 5Aza
and FLAG treated patients was comparable (MS not yet reached)
in contrast to shorter EFS of 5Aza patients crossing over to FLAG
(MS 18 mo). Tests of equality over groups are not signiﬁcant
(Log-Rank p0.1652), although data suggests better early EFS in
the 5Aza alone group. Of the initial 22 patients, 17 underwent
allogeneic transplant (median age 46, range 16-62). The remainder
were ineligible due to refractory disease, infection or comorbidi-
ties. Patients received targeted busulfan-based preparative regi-
mens; 9 received MRD and 8 MUD transplant. With median
follow up of 250 days(range 24-1304), EFS of the 5Aza group is
superior to the FLAG group (MS not yet reached); both are far
superior to the 5Aza to FLAG group(MS 7 mo; Log-Rank
p0.0448). All patients receiving chemotherapy had a higher rate
of early TRM compared with those receiving 5Aza alone. It is
unclear if the inferior EFS of the 5Aza to FLAG group is due to
higher TRM or identiﬁes patients at higher risk for early relapse.
While these cohorts are small, they represent the longest continu-
ing follow up of patients treated with this strategy, and their
survival compares very favorably with historical EFS for MDS.
These early results suggest 5Aza as initial cytoreductive therapy
before transplantation is a strategy worth pursuing in planned
larger multicenter trials to conﬁrm these promising outcomes.
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